NCT03572400View on ClinicalTrials.gov

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

November 29, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Pancreatic Cancer
Interventions
DRUG

Gemcitabine

Neoadjuvant: Weekly Gemcitabine 200 mg/m2 iv Adjuvant: Gemcitabine 1000mg/m2, D1, 8, 15 Q 4 weeks total 6cycles

DRUG

Durvalumab

Neoadjuvant: Durvalumab 1.5g iv Q 4weeks Adjuvant: Durvalumab 1.5g iv Q 4weeks for 1 year

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Do-Youn Oh

OTHER